- $2.73bn
- $2.50bn
- $4.09m
German 'magic mushroom' biotech Atai jumps 13% in Nasdaq debut
Thiel-backed psychedelics firm Atai valued at $3.19 bln in Nasdaq debut (updated)
Thiel-backed psychedelics startup Atai valued at over $3 bln in Nasdaq debut
Brief: Atai Life Sciences Shares Open At A Premium Of 40% In Nasdaq Debut Vs IPO Price
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 04:00 AM
Brief: Atai Life Sciences Announces Pricing Of Upsized Initial Public Offering